anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a knee protection medicine bag for treating wandering arthritis and a preparation method. The knee protection medicine bag is prepared from the following medicinal materials in parts by weight: 8 parts of radix sileris, 5 parts of angelica, 5 parts of safflower, 5 parts of processed radix aconiti, 5 parts of frankincense, 3 parts of monkshood and 3 parts of dried ginger. The preparation method comprises the following steps: grinding all medicinal materials into fine powder, putting the fine powder into a gauze bag, spreading the medicinal powder thinly and evenly, and carrying out stitching with a needle and threads so as to form small lattices. All traditional Chinese medicinal materials have the effects of warming meridians, promoting blood circulation, dispelling cold, eliminating swelling and alleviating pain. After the knee protection medicine bag is worn, along with the increase of temperature at knee joints, the medicines get hot slowly, and the properties of the medicines constantly volatilize into the body. The knee protection medicine bag has high pertinence on treating arthritis.
OXYGEN, COMPRESSED USP UN1072 PRODUCED BY AIR LIQUIFACTION OXYGEN 2   
WARNING: For emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation. For all other medical applications, Rx only. Uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Do not attempt to use on patients who have stopped breathing unless used in conjunction with resuscitative equipment. Keep out of reach of children. Federal law requires that this container be refilled with oxygen USP only by establishments registered as a drug manufacturer in accordance with the Federal Food, Drug and Cosmetic Act.   
DANGER: MAY CAUSE OR INTENCIFY FIRE; OXYDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Use and store only outdoors or in a well-ventilated place. In case of fire; Stop leak if safe to do so. Use a back flow preventive device in the piping. Use only with equipment of compatible materials of construction and rated for cylinder pressure. Use only with equipment cleaned for oxygen service. Open valve slowly. Close valve after each use and when empty. Protect from sunlight when ambient temperature exceeds 52 C (125 F). Read and follow the Safety Data Sheet (SDS) before use.   
CAS: 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL   
TECHGAS, INC. 22251 LEWES GEORGETOWN HWY GEORGETOWN, DE 19947 . 308-856-4111 

Revised: 11/2024

Document Id: 274c024b-4f04-dd1c-e063-6394a90a8f57

34391-3

Set id: 56078729-5700-4ae1-8b50-199700924dd7

Version: 13

Effective Time: 20241119

Techgas Inc.
Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
A total of 30 healthy men and women ages 18-79 years who are obese defined as body mass index (BMI) of 30 kg/m2 or greater and with prediabetes (defined as fasting blood glucose between 100-126 mg/dl, a fasting blood glucose of 140-199 mg/dl at 120 min during an oral glucose tolerance test; or HbA1C of 6-6.5%) will be enrolled and randomized to 4-5 weeks of salsalate or placebo in the study. CONTROL GROUP: Another n=10 healthy obese men and women age 18-49 WITHOUT prediabetes will be enrolled for baseline testing but will not undergo randomization to the salsalate/placebo intervention. Therefore, total enrollment will be n=40.

All subjects will have no history of cardiovascular, metabolic or pulmonary disease as determined from medical history and physical exam, and a resting 12-lead ECG. Subjects may be on anti-hypertensive medications but will be asked to hold the medication on the morning of testing. Subjects on medications for Type I or II diabetes mellitus or for hyperlipidemia will be excluded (see complete list below). Subjects will be non-smokers or quit smoking at least one year ago. Women will have regular menses and will be tested during the early follicular phase of their menstrual cycle (within 8 days of onset of menses) to control for differences in circulating estradiol concentrations. Aim 1 will measure microvascular function and aortic wall stiffness in obese prediabetic adults before and after 1 month of salsalate or placebo. Hypothesis 1 is that chronic inflammation inhibition will improve microvascular and large elastic artery function in obese adults with prediabetes. Aim 2 will measure muscle sympathetic nervous system activity (MSNA) and baroreflex sensitivity in obese prediabetic adults before and after 1 month of salsalate or placebo. Hypothesis 2 is that chronic inflammation inhibition will decrease MSNA and improve baroreflex sensitivity in obese adults with prediabetes.
In this study, the investigators aim determine whether patients with Parkinson's disease (PD) have altered perceptual decision-making. The results of these experiments will shed important light on some of the enigmatic symptoms seen in patients with disorders of movement.

In this study the subjects perform a computer generated visual task which involves reporting the direction of an arrow that is more or less difficult to see on the computer screen. Eye movements will be monitored using a video eye tracker. The system is completely non-invasive and positioned in front, out of the subject's line of sight to avoid interfering with their ability to perform the task.

Subjects will report their decision with either an eye movement in the same direction as the perception of the arrow direction. Trials will proceed as follows: a central point will appear on the screen. Subjects are asked to look at the fixation point. After this random delay time, a patch of spots will appear in place of the center fixation spot, embedded in the patch will be an arrow. The contrast between the arrow and the patch will vary from high values to low. At high contrasts the direction at which the arrow points will be very clear and at low contrasts it will be unclear. The task of the subject is to make a rapid eye movement as soon as they decide which direction the arrow points. A sound will be played to indicate a correct choice. On trials in which the sensory information is ambiguous subjects will be told to 'make their best guess' to which target the arrow points. Unknown to the subject the investigators will manipulate the probability that one of the targets is the correct one. This latter manipulation will test whether subjects can use probability information to inform their decisions. The investigators are particularly interested in whether this probability information is used preferentially when the sensory information is ambiguous.

The total number of subjects to be enrolled in the study is approximately 120. Subject groups are as follows: Healthy humans between the ages of 30 and 80 and those with PD (between ages of 45 and 80), dystonia (ages 30-80) and cerebellar lesions (ages 30-80) including those who have undergone DBS surgery to treat their PD or dystonia. The total duration of each session is approximately 2 hours. Each patient group including those with DBS will perform two sessions of the same task - one while on medication and one while off medication, hence the total duration of the study will be 4 hours for these groups (2 different sessions during different days). These patient groups are free to do these sessions at the same time as their routine physician visits or any other time that works best for them.
The invention discloses Chinese patent medicine in pill. The Chinese patent medicine is prepared from more than ten kinds of Chinese medicinal herbs that are ground into powder as well as honey and yellow wine. The raw materials of the Chinese patent medicine are widely available. The preparation method of the Chinese patent medicine is simple. The Chinese patent medicine has a special therapeutic effect on cerebrovascular diseases, and can cure the patient in half a month during which the patient are prohibited from taking rape oil and grapes. The Chinese patent medicine has the advantages of immediate effect and no toxic and side effect, safety, and economy and practicality.
Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of bimatoprost ophthalmic solution 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.

Do not reuse applicators and do not use any other brush/applicator to apply bimatoprost ophthalmic solution.

Do not apply to the lower eyelash line [see Warnings and Precautions (5.3, 5.4) and Patient Counseling Information (17)].

Additional applications of bimatoprost ophthalmic solution will not increase the growth of eyelashes.

Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.
This study was a 3-arm, parallel group, randomized, patient- and investigator-masked trial planned in 90 patients with Diabetic macular edema (DME). The study consisted of a screening period of 60 days, main study (12 weeks), and an extension period (12 weeks). The study was stratified such that sentinel safety cohorts were first enrolled to test the safety of the combination of LKA651 and Lucentis before proceeding with further patient randomization. After determination of safety from Day 15 data from each sentinel cohort, patients were enrolled into 1 of 3 arms: LKA651 monotherapy, LKA651 plus Lucentis, and Lucentis monotherapy. Every patient was dosed 3 times in 4 week intervals in the treatment phase and was then followed up for an extension phase of an additional 12 weeks during which Lucentis was allowed to be administered as rescue at the discretion of the Investigator. No predefined rescue criteria were outlined as guidance.
Collagen is characterized by its high content of glycine, proline and hydroxyproline, and it is found to exert beneficial effects on several health benefits. Recent evidence suggests that the consumption of amino acids and/or peptides abundantly present in collagen may have the capacity to influence the synthesis of new collagen in the body. Indeed, it has been found that collagen supplements improve skin moisture, elasticity, and hydration when orally administered. Additionally, collagen reduces the wrinkling and roughness of the skin, and existing studies have not found any side effects of its oral supplements. Thus, to exert any beneficial effects, it is essential that hydrolyzed collagen is optimally absorbed. This study aimed to investigate the postprandial absorption of collagen and elucidate the absorption rate and bioavailability after oral intake.

The study personnel will prepare the drinkable solutions containing the study products in a room accessible to site staff only. Drinkable solutions will be provided to subjects just before consumption. Product ingestion will be early in the morning after overnight fasting for 12 h. On the morning of the experiment, subjects will fast and each subject will take the products orally. Dosage (Quantity of product to consume orally): This is calculated depending on the body weight; 400 mg/kg of body weight with 20 w/v % water. Collagen products (fine powder) will be diluted in water prior consumption. Control group ingest approximately same amount of plain water. Participants cannot drink water within 4 hours before and after the product consumption.

The assessment of the bioavailability of the four collagen-based treatments (CP1, CP2, CP3, CP4) will be evaluated by quantifying 8 di/tri-peptides and the amino acid profile in the blood of 25 volunteers by LC-MS.
Combination therapy with the preliminary RP2D A of MK-4830, and pembrolizumab, in participants who have histologically-confirmed, first-line treatment advanced non-small-cell-lung-cancer (NSCLC) (Stage IIIB or IV). MK-4830 will be administered IV following pembrolizumab infusion, Q3W, starting with Cycle 1, Day 1, for a maximum of 35 cycles. Each cycle is 21 days. Pembrolizumab will be administered by IV, Q3W, starting with Cycle 1, Day 1. Each cycle is 21 days. The combination may be administered for a maximum of 35 cycles (up to approximately 2 years).
Post-inflammatory hyperpigmentation (PIH) is a hypermelanosis that often occurs secondary to skin irritation or injury, especially in darker skin tones, for which there is currently a lack of effective treatment options. Few preclinical models are available to study PIH. Here, we show that the Yucatan miniature pig consistently develops PIH after skin injuries. Skin wounds were produced on Yucatan pigs by needle punches, full-thickness excisions, or burns. Wound sites were monitored and photographed regularly. Tissue samples were collected after 24 weeks and processed for histology/immunohistochemistry. Skin pigmentation and histologic changes were quantified by computer-assisted image analyses. All injury methods resulted in hyperpigmentation. Melanin content at the histologic level was quantified in the larger (burn and excision) wounds, showing a significant increase compared to uninjured skin. Increased melanin was found for both epidermal and dermal regions. Dermal melanin deposits were primarily clustered around the papillary vasculature, and were associated not with melanocytes but with leukocytes. The Yucatan miniature pig model recapitulates key clinical and histologic features of PIH in humans, including skin hyperpigmentation at both gross and histologic levels, and persistence of dermal melanin subsequent to injury. This model could be used to further our understanding of the etiology of PIH, and for new therapy development.
PURPOSE:To provide the subject new compound having an antitumor activity and useful as an antitumor agent. CONSTITUTION:A compound of the formula or its salt. The appearance; white powder; molecule formula; C30H48O2N2; melting point: 151-153 deg.C; solubility: soluble in chloroform, pyridine, etc., insoluble in water and hexane. The compound is obtained by aerobically culturing a microorganism [e.g. Streptomyces-sp. HC 34 strain (FERM-BP-3680] belonging to the genus Streptomyces and having an ability to produce the HC 34 and subsequently separating the compound from the cultured product. The culture is preferably carried out at 25-30 deg.C by an aerobic liquid medium culturing method. The collection of the objective compound from the culture product is performed e.g. by extracting the filtered cultured solution with ethyl acetate, allowing silica gel, etc., to adsorb the extract solution and subsequently eluting the adsorbed compound.
FIELD: medicine. SUBSTANCE: method for rehabilitation of patients ill with alcoholism and prophylaxis of recurrences includes psychotherapy within which disactualization of morbid attraction to alcohol intensified in remission, working out of new stereotypes of behaviour and patienrt adaptation with the help of social-psychological training. Besides, patient should on one's own, just after wakening after sleep massage by pressing his lobules of the ear and repeat the formula of self-conciousness. 15-20 min prior to taking meal, introduced peroally are two-three spoons of decoction of sage-brush and thyme in ratio of 1:4, and before sleep, patient should repeat the self-conciousness formula with the aid of visual-motor reaction. EFFECT: higher efficiency of rehabilitation and prophylaxis of recurrences in patients ill with alcoholism. 5 cl
PURPOSE: Vestibular migraine (VM) is a disorder with prominent vestibular symptoms that are causally correlated with migraine and is the most prevalent neurological cause of episodic vertigo. Nevertheless, the functional underpinnings of VM remain largely unclear. This study aimed to reveal concordant alteration patterns of functional connectivity (FC) in VM patients.
METHODS: We searched literature measuring resting-state FC abnormalities of VM patients in PubMed, Embase, Cochrane, and Scopus databases before May 2023. Furthermore, we applied the anisotropic effect size-signed differential mapping (AES-SDM) to conduct a whole-brain voxel-wise meta-analysis to identify the convergence of FC alterations in VM patients.
RESULTS: Nine studies containing 251 VM patients and 257 healthy controls (HCs) were included. Relative to HCs, VM patients showed reduced activity in the left superior temporal gyrus and left midcingulate/paracingulate gyri, and increased activity in the precuneus, right superior parietal gyrus, and right middle frontal gyrus. Jackknife's analysis and subgroup analysis further supported the generalization and robustness of the main results. Furthermore, meta-regression analyses indicated that the Dizziness Handicap Inventory (DHI) ratings were positively correlated with the activity in the precuneus, while higher Headache Impact Test-6 and DHI scores were associated with lower activity within the left midcingulate/paracingulate gyri.
CONCLUSIONS: The study indicates that VM is associated with specific functional deficits of VM patients in crucial regions involved in the vestibular and pain networks and provides further information on the pathophysiological mechanisms of VM.
BACKGROUND: Accurate leaf water potential (Ψw) determination is crucial in studying plant responses to water deficit. After excision, water potential decreases, even under low evaporative demand conditions, which has been recently attributed to the equilibration of pre-excision Ψw gradients across the leaf. We assessed the influence of potential re-equilibration on water potential determination by monitoring leaf Ψw and relative water content decline after excision using different storage methods.
RESULTS: Even though leaf Ψw declined during storage under low evaporative demand conditions, this was strongly reduced when covering the leaf with a hydrophobic layer (vaseline) and explained by changes in relative water content. However, residual water loss was variable between species, possibly related to morpho-physiological leaf traits. Provided water loss was minimized during storage, pre-excision leaf transpiration rate did not affect to the magnitude of leaf Ψw decline after excision, confirming that transpiration-driven Ψw gradients have no effect on leaf Ψw determination.
CONCLUSIONS: Disequilibrium in water potentials across a transpiring leaf upon excision is dissipated very quickly, well within the elapsed time between excision and pressurization, therefore, not resulting in overestimation of leaf Ψw measured immediately after excision. When leaf storage is required, the effectiveness of a storage under low evaporative demand varied among species. Covering with a hydrophobic layer is an acceptable alternative.
The roles of Aβ low-threshold mechanoreceptors (LTMRs) in transmitting mechanical hyperalgesia and in alleviating chronic pain have been of great interest but remain contentious. Here we utilized intersectional genetic tools, optogenetics, and high-speed imaging to specifically examine functions of SplitCre labeled mouse Aβ-LTMRs in this regard. Genetic ablation of SplitCre-Aβ-LTMRs increased mechanical nociception but not thermosensation in both acute and chronic inflammatory pain conditions, indicating a modality-specific role in gating mechanical nociception. Local optogenetic activation of SplitCre-Aβ-LTMRs triggered nociception after tissue inflammation, whereas their broad activation at the dorsal column still alleviated mechanical hypersensitivity of chronic inflammation. Taking all data into consideration, we propose a model, in which Aβ-LTMRs play distinctive local and global roles in transmitting or alleviating mechanical hyperalgesia of chronic pain, respectively. Our model suggests a strategy of global activation plus local inhibition of Aβ-LTMRs for treating mechanical hyperalgesia.
PURPOSE:To obtain a poultic with an adhesive tape generating no shift by providing the poultic wherein plaster is spread and applied to the upper surface of a support, the adhesive tape holding the poultice to an adhesive surface so that the adhesive peripheral edge thereof protrudes along the outer periphery of the poultice and a release liner covering the surface of the plaster of the poultice and the adhesive peripheral edge of the adhesive tape. CONSTITUTION:A poultice with an adhesive tape is equipped with the adhesive tape 24 holding a poultice 23 on an adhesive surface 34 so that the adhesive peripheral surface of said tape protrudes along the outer periphery of the poultice 23 laminated and formed on a support 21 by spreading and applying plaster 22 to one surface of said support and the release liner 25 covering the plaster 22 of the poultice 23 and the adhesive surface 34 of the adhesive peripheral edge of the adhesive tape 24. The width of the adhesive peripheral edge provided so as to protrude along the outer periphery of the poultice 23 is pref. 5-10mm. That is, when the width is 5mm or less the poultice becomes impossible to withstand the lowering of adhesive strength accompanied by the extension and contraction of the affected part and, when the width is 10mm or more, it is necessary to widely take the area of the adhesive tape to cause an increase in cost. The adhesive tape 24 has function allowing the plaster 22 and the support 21 to fit to the skin and preventing the protrusion of a medicine from the circumference.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel arylalkylthia- diazinones of the formula (I)   where R 1  means H; R 2  means H or A; R 3  means OH, -OR 10 ; R 4  means -OH or OR 10 ; R 5  means unsubstituted phenyl residue or that mono- or bisubstituted with R 6 ; and/or R 7 ; Q is absence or means alkylene with 1-6 C-atoms; R 6  and R 7  each and independently each of other means NH 2 ,-NR 8  R 9 ,-NO 2  where R 8  and R 9  each and independently each of other means H; acyl with 1-8 C-atoms that can be substituted with 1-5 fluorine atoms and/or chlorine atoms; -COOA, -SO 2 A where A means alkyl with 1-6 C-atoms that can be substituted with 1-5 fluorine atoms and/or chlorine atoms; R 10  and R 11  each and independently each of other means A, cycloalkyl with 3-7 C-atoms and their physiologically acceptable salts also. Compounds show inhibitory effect with respect to phosphodieste-rase-IV and can be used for treatment of patients with asthma diseases. Also, they inhibit activity with respect to formation of tumor necrosis factor and useful for treatment of patients with allergic and inflammatory diseases. Invention describes also method of synthesis of compounds of the formula (I), pharmaceutical composition and method of its preparing. EFFECT: improved method of synthesis, valuable medicinal properties. 4 cl, 10 ex